Participated · Series B · Jun 2026

Ollin Biosciences, founded in 2023 and based in Austin, Texas, is advancing a pipeline of bispecific antibodies for retinal and orbital diseases. Its lead candidate, OLN324, is a next-generation VEGF/Ang2 bispecific antibody discovered in collaboration with Innovent Biologics; in a 164-patient randomized head-to-head Phase 1b (JADE) study versus faricimab (Vabysmo®) OLN324 demonstrated faster and greater anatomic retinal drying and numerically greater vision gains. Ollin plans to initiate global Phase 3 trials of OLN324 in DME and wAMD in the second half of 2026 after completing regulatory discussions with the FDA and receiving EMA scientific advice. The company’s second program, OLN102, is a TSHR/IGF-1R bispecific antibody discovered with VelaVigo and is expected to enter clinical development in 2026 for thyroid eye disease and Graves’ disease. Ollin positions its candidates as potentially best-in-disease therapies and is using recent financing to fund registrational studies and further clinical development.

Participated · Series A · Jun 2026

Founded in 2021, RQ Bio is developing long-acting monoclonal antibody therapeutics aimed at providing immediate and durable protection against seasonal influenza. Its lead programme, RQB01, is in IND-enabling studies and is designed to deliver broad strain coverage and extended duration of action via a differentiated dual mechanism targeting conserved epitopes. The company aims to provide season-long protection with a single administration, particularly for immunocompromised and high-risk patients. RQ Bio has an experienced team with prior success in developing long-acting antiviral antibodies and is backed by a syndicate of life sciences investors. The recent $115 million Series A will fund clinical development of RQB01 and further advance the company's antibody discovery platform. Leadership was strengthened with the appointment of Christian S. Schade as Executive Chairman.

Led · Series B · Jan 2026

Nocion Therapeutics is advancing taplucainium (formerly NTX-1175), a first-in-class, once-daily dry-powder inhaled charged sodium channel blocker (CSCB) that selectively silences activated airway nociceptors while minimizing systemic exposure. The company positions taplucainium as a potentially best-in-class therapy for the roughly nine million U.S. patients suffering from refractory or unexplained chronic cough, a field with no new FDA-approved drugs in 65 years. Taplucainium is currently being evaluated in the ASPIRE Phase 2b trial enrolling patients across the U.S., Canada, the U.K., and Europe, with topline data expected in mid-2026. Proceeds from the latest financing will fund trial completion, an End-of-Phase 2 meeting, and CMC work in preparation for late-stage studies, giving Nocion an operating runway through 2027. Beyond cough, the company’s CSCB platform may be applied to other conditions involving activated sensory neurons such as itch and pain. Nocion is headquartered in Watertown, Massachusetts, and was founded on intellectual property licensed from Harvard University and Boston Children’s Hospital. To date, the company has raised $93 million in Series B funding, including the recent extension.

Participated · Series A · Dec 2025

Prolynx is building a portfolio of extended-duration incretin and non-incretin medicines engineered for once-monthly or once-quarterly dosing to improve adherence and tolerability in obesity treatment. Its proprietary half-life extension platform, which has already shown clinical proof-of-concept in oncology, enables the creation of peptide drugs with markedly prolonged activity. The company is channeling its R&D toward IND-enabling studies and early clinical proof-of-concept for multiple obesity candidates. Newly appointed CEO Chris Boulton, a veteran of Amgen, Sanofi, and AstraZeneca, brings deep commercialization experience in metabolic disorders. Founders Daniel Santi and Gary Ashley continue to guide scientific strategy, with Santi serving as Chief Technical and Scientific Officer. Headquartered in Emeryville, California, Prolynx is backed by leading life-science investors and recently strengthened its balance sheet with a $70 million Series A to fund pipeline advancement.

Participated · Series A · Oct 2025

Elevara Medicines is a clinical-stage biotechnology company focused on creating novel therapeutics for rheumatoid arthritis (RA) and related chronic inflammatory conditions. Its lead asset, ELV001, is a potent, selective, first-in-class oral CDK4/6 inhibitor licensed globally from Teijin Pharma after more than a decade of prior research. The drug is being positioned as an add-on treatment for RA patients who have an inadequate response to methotrexate and TNF inhibitors, aiming to reduce cycling among multiple immunosuppressive therapies. Elevara plans to launch the START-SYNERGY Phase 2 trial before the end of 2025, enrolling approximately 180 such patients. Beyond RA, the company is running exploratory programs in additional inflammatory indications and women’s health. The business was co-founded by clinical advisory group Weatherden with backing from Monograph Capital and is led by CEO Emma Tinsley and CMO Professor Dominique Baeten. Governance is supported by a board that includes representatives from Monograph Capital, Forbion, Sofinnova Partners and an independent director. Elevara recently secured $70 million in Series A funding to finance the Phase 2 trial and advance its broader pipeline.